Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hyung Heon Kim
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.96
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -28.41
Financials
Net Income
$-4.62MEBITDA
$-4.62MFree Cash Flow
$-3.74MEPS (diluted)
$-0.69Shares Outstanding (diluted)
6.68M+4770792.9%Operating Expenses
$4.69MCash & Debt
$8.78MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.97M | $-7.35 |
| 2024 | $0.00 | $-27.59M | $-39.16 |
| 2023 | $0.00 | $-12.47M | $-27.06 |
| 2022 | $0.00 | $-13.97M | $-477.84 |
| 2021 | $0.00 | $-15.28M | $-1742.40 |
| 2020 | $0.00 | $-29.68M | $-4831.20 |
| 2019 | $0.00 | $-21.31M | $-10771.20 |
| 2018 | $0.00 | $-15.53M | $-112860.00 |
| 2017 | $0.00 | $-33.41M | $-213180.00 |
| 2016 | $0.00 | $-14.59M | $-106454.37 |
| 2015 | $0.00 | $-9.03M | $-93780.39 |
| 2014 | $0.00 | $-320.0K | $-2300.65 |
Valuation
MTVAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-15.79%Social Signal Score
Mentions (8)
- Newsprnewswire.com·5d ago·Negative
…ected in First Quarter of 2027; Phase 2 Study in MetALD and ALD Planned for Second Half of 2027 CAMBRIDGE, Mass., Nov. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist.
View source ↗ - Newsprnewswire.com·6d ago·Negative
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 Statistically Significant Increase in Liver and Circulating FGF21 Expression Greater Glucose Lowering and Comparable Weight Loss vs. Retatrutide with Less Reliance on Appetite Suppression MetaVia Preparing to Initiate a Phase 2 Study in MetALD and ALD in the Second Half of 2027 CAMBRIDGE, Mass.
View source ↗ - Newsprnewswire.com·9d ago·Neutral
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and Vanoglipel Full Data From the Phase 1 Parts 3A and 3B Expected in the First Quarter of 2027 CAMBRIDGE, Mass.
View source ↗ - Newsprnewswire.com·10d ago·Negative
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD Additional Phase 1 Part 3B Data Highlight DA-1726's 1.47
View source ↗ - Newsprnewswire.com·13d ago·Neutral
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026 CAMBRIDGE, Mass., Nov. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for a poster presentation at ObesityWeek® 2026, taking place November 14-17, 2026, in Washin…
View source ↗ - Newsprnewswire.com·25d ago·Neutral
…se 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation …
View source ↗ - Newsprnewswire.com·40d ago·Negative
…pment Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the appointment of Sarah Browne, M.D.
View source ↗ - Newsprnewswire.com·74d ago·Neutral
…ce-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tis…
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.83 per share
Typical surprise +12.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.69 vs $-0.73beat
- Thu, Aug 6$-0.90 vs $-0.82miss
- Thu, May 14$-0.79 vs $-0.76miss
- Thu, Mar 26$1.01 vs $-2.06beat
- Thu, Nov 6$-1.54 vs $-2.86beat
- Thu, Aug 7$-2.86 vs $-3.52beat
Estimates and results for MTVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MTVA officers and directors.
- Bought
- $3.3m
- Sold
- —
2 trades
0 trades
- Woodworth Marshall Hbought
- Dong-a St Co., Ltdbought
20 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MTVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
